Search the Newsreel

Chief Financial Officer At Stevanato Group Sells $84K Of Stock

Marco Lago Dal, the Chief Financial Officer at Stevanato Group (NYSE: STVN), recently sold 4,209 shares of the company's stock for a total transaction value of $84,558. This insider sell, reported in an SEC Form 4 filing, comes as Stevanato Group's shares were up …

Stevanato Group (STVN) Could Be 16% Undervalued Following Earnings And Guidance Update

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. What Stevanato Group's latest earnings and guidance mean for investors Stevanato Group (STVN) has …

How Investors Are Reacting To Stevanato Group (STVN) Trimmed Guidance And New GLP-1 Pen Approvals

Stevanato Group S.p.A. recently reported past second-quarter 2026 results showing sales of €302 million with lower net income, slightly trimmed its full-year revenue guidance to €1.26–€1.28 billion, and outlined expected diluted EPS of €0.53–€0.55. At the same time, the company's Alina pen injector platform …

Stevanato Group (STVN) Stock Looks Cheap On Cash Flow But Pricey On Earnings

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Stevanato Group stock has declined 34.6% over the past three years, and current checks send mixed valuation signals, with an intrinsic value estimate …

Stevanato Group S.p.A. (STVN): Investor Outlook Reveals 23.83% Potential Upside

Stevanato Group S.p.A. (STVN), a healthcare company specializing in medical instruments, is currently trading at $20.27 with a market capitalization of $5.53 billion. Analysts predict a potential upside of 23.83%, with an average target price of $25.10. Despite negative free cash flow, the company …

How Q2 Results and Alina GLP-1 Approvals At Stevanato Group (STVN) Have Changed Its Investment Story

Stevanato Group (STVN) recently reported mixed Q2 2026 results with increased sales but decreased net income and slightly narrowed full-year guidance. Simultaneously, European marketing authorizations for its Alina GLP-1 variable-dose pen injector platform highlight the company's growing presence in self-administered injectable therapies, offering tangible …

Stevanato Group S.p.A. SEC Filing (Aug 7, 2026)

Stevanato Group S.p.A. (STVN) filed a Form 144 with the SEC on August 7, 2026, indicating a proposed sale of 4,209 ordinary shares by Citigroup Global Markets, Inc. The shares were acquired on August 6, 2026, through restricted stock vesting as payment for services …

Liraglutide combination products using Stevanato Group pen gain European approval

Stevanato Group's liraglutide-based combination products, utilizing their Alina pen injector platform, have received marketing authorizations in Europe. The approvals are for Alina 30, designed for diabetes therapies, and Alina 50, intended for weight management applications, both part of a broader variable-dose platform for injectable …

Stevanato Group (NYSE: STVN) targets 26.8% 2026 EBITDA margin

Stevanato Group reported strong Q2 2026 results with an 8% revenue increase and a 26% adjusted EBITDA margin, driven by growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and High Value Solutions. The company updated its full-year 2026 guidance, targeting a 26.8% adjusted …

Stevanato Group S.p.A. Stock 12‑Month Price Target Raised to $25.1, Implies 28% Upside

Stevanato Group S.p.A.'s average stock price target has been raised from $24.95 to $25.1 by 10 analysts, suggesting a potential 28% upside from the August 4th closing price. The consensus rating among 12 covering analysts remains a "Buy," with 10 Buys and 2 Holds. …

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. That's …

Stevanato Group Details Mid-2026 Performance and Risk Landscape in Unaudited Interim Report

Stevanato Group has filed an unaudited interim report for Q2 2026, outlining its financial performance and discussing key operational risks such as supply chain issues, geopolitical tensions, and post-pandemic demand normalization. The report emphasizes the importance of quality, innovation, and brand reputation for competitiveness. …

335,493 Shares in Stevanato Group S.p.A. $STVN Purchased by Confluence Investment Management LLC

Confluence Investment Management LLC has purchased a new stake of 335,493 shares in Stevanato Group S.p.A., valued at approximately $6.06 million, representing 0.11% of the company. Other institutional investors like Conestoga Capital Advisors, Van Berkom & Associates, Jennison Associates, and Roubaix Capital also increased …

Stevanato Group SpA (STVN) (Q2 2026) Earnings Call Highlights: Biologics Surge and Alina ...

Stevanato Group (STVN) reported an 8% revenue increase in Q2 2026, driven by a 9% rise in biopharmaceutical and diagnostic solutions and a 30% surge in biologics revenue. The company saw an adjusted EBITDA margin expansion to 26% and achieved a significant milestone with …

Stevanato Group (STVN) Stock Faces Cash Strain Despite Margin Gains

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported an 8% revenue increase in Q2 2026, driven by a 9% rise in biopharmaceutical and diagnostic solutions and a 30% surge in biologics revenue. The company saw an adjusted EBITDA margin expansion to 26% and achieved a significant milestone with …

Stevanato Group SpA Revenue Breakdown – MUN:87N

Stevanato Group SpA (MUN:87N) reported a total revenue of €1.19 billion last year. The majority of this revenue, €997.60 million, came from its Biopharmaceutical and Diagnostic Solutions segment. EMEA was the largest contributing region, generating €663.30 million.

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group reported an 8% increase in revenue for the second quarter of fiscal 2026, reaching €302.0 million, primarily driven by its Biopharmaceutical and Diagnostic Solutions Segment. The company also updated its full-year 2026 guidance, expecting revenue between €1.260 billion and €1.280 billion, and …

Craftech Holdco acquired Balda C. Brewer, Inc. from Stevanato Group S.p.A..

Craftech Holdco successfully acquired Balda C. Brewer, Inc. from Stevanato Group S.p.A. on June 30, 2026. This transaction involved Stevanato Group S.p.A., which is listed on the NYSE under the ticker STVN. The news was published on August 4, 2026, at 5:23 pm EDT.

Stevanato Group (NYSE: STVN) grows H1 revenue, records disposal loss

Stevanato Group (NYSE: STVN) grows Q2 sales 8% and updates 2026 view

Stevanato Group (NYSE: STVN) announced an 8% increase in Q2 2026 sales, primarily driven by a 9% rise in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and strong demand for High-Value Solutions (HVS), which grew 16%. The company also updated its full-year 2026 guidance, …

Stevanato Group (NYSE: STVN) grows Q2 revenue and sells Balda subsidiary

Stevanato Group (NYSE:STVN) Releases Earnings Results, Beats Expectations By $0.01 EPS

Stevanato Group (NYSE:STVN) Updates FY 2026 Earnings Guidance

Sage Park Acquires Balda C. Brewer, the California-based Contract Manufacturing Injection Molding Subsidiary From Stevanato Group S.p.A.

ANAHEIM, CA / ACCESS Newswire / August 4, 2026 / Craftech Holdco, a portfolio company of Sage Park, today announced the acquisition of Balda C. Brewer ("BCB"), the Ontario, California-based contract manufacturing subsidiary, from its parent company, Stevanato Group S.p.A ("Stevanato"). BCB is a …

Stevanato Group Q2 2026 Earnings Call: Complete Transcript

Stevanato Group reported an 8% year-over-year revenue growth in Q2 2026, reaching $302 million, driven by strong demand for injectable biologics and GLP-1 therapies. The company divested its California subsidiary, Balda C. Brewer, to focus on higher-value integrated drug delivery systems, a move expected …

Stevanato Group (STVN) Q2 Earnings Top Estimates

Stevanato Group (STVN) reported Q2 earnings of $0.16 per share, surpassing the Zacks Consensus Estimate of $0.15, and revenues of $351.09 million, which slightly missed the consensus. The company has consistently beaten EPS estimates over the past four quarters and currently holds a Zacks …

Stevanato Group SpA earnings beat by €0.01, revenue topped estimates

Stevanato Group SpA (NYSE: STVN) reported strong second-quarter results, with EPS of €0.14 surpassing analyst estimates by €0.01 and revenue reaching €302M, exceeding the consensus estimate of €298.64M. The company's stock has seen a 14.20% increase in the last three months, despite a 10.83% …

Investors brace for Stevanato earnings amid GLP-1 packaging surge By Investing.com

Stevanato Group SpA is set to report its second-quarter earnings, with analysts expecting significant year-over-year growth in EPS and revenue. Investors are keenly watching the company's ability to leverage the booming GLP-1 obesity drug market and the broader biologics expansion, focusing on its shift …

(STVN) Volatility Zones as Tactical Triggers

This article analyzes Stevanato Group S.p.a. (NASDAQ: STVN) using AI models to provide tactical trading triggers. It highlights a potential shift in near-term sentiment and offers three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis …

Stevanato Group (STVN) Could Be 19% Undervalued As Alina Pen Approvals Expand In Europe

Stevanato Group (STVN) is experiencing mixed share price momentum despite recent marketing authorizations for its Alina 30 and Alina 50 pen injectors in Europe. The company is considered 18.6% undervalued with a fair value of $24.39, driven by increasing demand for its drug delivery …

Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries

Stevanato Group's Alina® pen injector platform has received marketing authorizations in multiple European countries for liraglutide-based combination products used in diabetes and weight management therapies. This expansion signifies broader commercial adoption of the Alina® 30 and Alina® 50 variants, highlighting Stevanato Group's commitment to …

Stevanato’s Alina pen injector gains EU approval for liraglutide

Stevanato Group S.p.A. announced that its Alina pen injector platform has received marketing authorizations in Europe for liraglutide-based combination products. The approval covers Alina 30 for diabetes therapies and Alina 50 for weight management. The Alina platform is a variable-dose, disposable pen injector designed …